Literature DB >> 23007479

Biliary tract: Is there a role for neoadjuvant and adjuvant therapy in biliary cancer?

William R Jarnagin.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23007479     DOI： 10.1038/nrgastro.2012.186

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  6 in total

Review 1.  Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.

Authors:  Anne M Horgan; Eitan Amir; Thomas Walter; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

2.  Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.

Authors:  Evan S Glazer; Ping Liu; Eddie K Abdalla; Jean-Nicolas Vauthey; Steven A Curley
Journal:  J Gastrointest Surg       Date:  2012-07-10       Impact factor: 3.452

3.  Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.

Authors:  William R Jarnagin; David S Klimstra; Michael Hezel; Mithat Gonen; Yuman Fong; Kevin Roggin; Karina Cymes; Ronald P DeMatteo; Michael D'Angelica; Leslie H Blumgart; Bhuvanesh Singh
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?

Authors:  Flavio G Rocha; Hwajeong Lee; Nora Katabi; Ronald P DeMatteo; Yuman Fong; Michael I D'Angelica; Peter J Allen; David S Klimstra; William R Jarnagin
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

6.  Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

Authors:  John P Neoptolemos; Malcolm J Moore; Trevor F Cox; Juan W Valle; Daniel H Palmer; Alexander C McDonald; Ross Carter; Niall C Tebbutt; Christos Dervenis; David Smith; Bengt Glimelius; Richard M Charnley; François Lacaine; Andrew G Scarfe; Mark R Middleton; Alan Anthoney; Paula Ghaneh; Christopher M Halloran; Markus M Lerch; Attila Oláh; Charlotte L Rawcliffe; Caroline S Verbeke; Fiona Campbell; Markus W Büchler
Journal:  JAMA       Date:  2012-07-11       Impact factor: 56.272
  6 in total
  2 in total

Review 1.  Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives.

Authors:  Marco Imperatori; Loretta D'Onofrio; Eleonora Marrucci; Francesco Pantano; Alice Zoccoli; Giuseppe Tonini
Journal:  Hepat Oncol       Date:  2015-11-30

2.  Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.

Authors:  Hye Rim Ha; Do-Youn Oh; Tae-Yong Kim; KyoungBun Lee; Kyubo Kim; Kyung-Hun Lee; Sae-Won Han; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Yung-Jue Bang
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.